Company Overview of Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops a portfolio of late stage pharmaceutical products for the treatment of chronic pain. Its products include COL-003 oxycodone, COL-172 oxymorphone, and COL-195 and COL-196 to treat pain; and COL-171 to treat ADHD. The company, through its subsidiary, Onset Therapeutics, LLC, also develops and commercializes products for skin and skin related illnesses and disorders. Collegium Pharmaceutical, Inc. was founded in 2002 and is based in Cumberland, Rhode Island.
400 Highland Corporate Drive
Cumberland, RI 02864
Founded in 2002
Key Executives for Collegium Pharmaceutical, Inc.
Founding President of Precision Dermatology
Vice President of Technical Operations
Vice President of Business Development
Director of Product Research & Development
Compensation as of Fiscal Year 2013.
Collegium Pharmaceutical, Inc. Key Developments
Collegium Pharmaceutical, Inc. Presents at Jefferies 2013 Global Healthcare Conference, Jun-04-2013 03:00 PM
May 21 13
Collegium Pharmaceutical, Inc. Presents at Jefferies 2013 Global Healthcare Conference, Jun-04-2013 03:00 PM. Venue: Grand Hyatt Hotel, 109 East 42nd Street at Grand Central, New York, New York, United States. Speakers: Michael P. Heffernan, Co-Founder, Chief Executive Officer, President and Director.
Collegium Pharmaceutical, Inc. Presents at UBS Global Healthcare Conference, May-20-2013 01:30 PM
May 9 13
Collegium Pharmaceutical, Inc. Presents at UBS Global Healthcare Conference, May-20-2013 01:30 PM. Venue: Sheraton New York Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: Michael P. Heffernan, Co-Founder, Chief Executive Officer, President and Director.
Collegium Pharmaceutical, Inc. Announces Top-Line Results from its Phase I Clinical Trial for Oxycodone DETERx®
Apr 17 13
Collegium Pharmaceutical, Inc. announced top-line results from its recently completed Phase I clinical trial for Oxycodone DETERx®, its extended-release, abuse-deterrent, multi-particulate product in a capsule form. The product utilizes Collegium’s DETERx® technology and is designed to be more resistant to tampering and abuse than traditional formulations of the drug and is currently in Phase 3 development. The product’s abuse-deterrent characteristics are being evaluated in laboratory and clinical studies, consistent with the recently-issued FDA Guidance titled Abuse-Deterrent Opioids - Evaluation and Labeling. The objective of the recently-completed study was to assess the safety and pharmacokinetics of Oxycodone DETERx® following various tampering methods compared to two controls; Oxycodone DETERx®, taken as an intact capsule, and immediate release oxycodone solution. This single dose, open-label, cross-over comparison study was conducted in 44 healthy subjects. The tampering methods used in this study are commonly employed by abusers to destroy the time-release mechanism of tablet and capsule formulations to make the drug more abusable. The two tampering techniques that were studied included opening the capsule and chewing the contents as well as crushing the contents. The selected crushing technique was previously identified in the laboratory as the most effective method of reducing the particle size of the product. In addition, chewing was studied as it a very common method of tampering that has been shown to effective in compromising the time-release of both conventional and newer, abuse-deterrent formulations. Both the crushed and chewed contents of DETERx® capsules were bioequivalent to intact DETERx® capsules in the fed state, demonstrating that crushing or chewing the contents of DETERx® capsules does not alter the pharmacokinetics. Chewing and crushing the capsule contents in either fed or fasted conditions resulted in mean Cmax values that were lower than the intact capsule when taken fed. The company intends to release detailed study results in the coming weeks.
Similar Private Companies By Industry
Recent Private Companies Transactions
August 27, 2013